Medicine and Dentistry
Acute Myeloid Leukemia
28%
Arm
8%
B-Cell Chronic Lymphocytic Leukemia
57%
Body Mass Index
14%
Bortezomib
32%
Chronic Myelogenous Leukemia
28%
Clinical Trial
28%
Cyclophosphamide
28%
D-Dimer
28%
Daratumumab
28%
Dexamethasone
28%
Diseases
16%
Disseminated Intravascular Coagulation
28%
False Negative Result
7%
Fibrinolysis
7%
Fludarabine
28%
Frailty
65%
Frailty Index
14%
Geriatrics
28%
Hazard Ratio
21%
Health Status
17%
Ibrutinib
28%
Induction Chemotherapy
20%
Malignant Neoplasm
7%
Metastatic Breast Cancer
57%
Minimal Residual Disease
36%
Multiple Myeloma
100%
Myeloma
22%
Obinutuzumab
28%
Overall Survival
70%
Patient-Reported Outcome
11%
Physical Performance
5%
Prevalence
7%
Prognostic Factor
30%
Progression Free Survival
19%
Proportional Hazards Model
6%
Quality of Life
57%
Receptor
28%
Recurrent Disease
14%
Rituximab
28%
Sarcopenia
28%
Sarcopenic Obesity
19%
Skeletal Muscle
9%
Survival Prediction
28%
Survival Rate
35%
Targeted Therapy
28%
Thalidomide
28%
Trastuzumab
28%
Treatment Duration
31%
Venetoclax
57%
Pharmacology, Toxicology and Pharmaceutical Science
Bortezomib
9%
Chemotherapy
42%
Chronic Lymphatic Leukemia
57%
Clinical Trial
28%
Comorbidity
5%
Cyclophosphamide
28%
Deterioration
9%
Diseases
8%
Dyspnea
5%
Esophagus Cancer
28%
Fludarabine
28%
Frailty
76%
Health Status
34%
Hematologic Malignancy
6%
Malignant Neoplasm
15%
Melphalan
9%
Metastatic Breast Cancer
57%
Minimal Residual Disease
5%
Multiple Myeloma
68%
Myeloma
20%
Obinutuzumab
28%
Overall Survival
36%
Paclitaxel
28%
Pharmacokinetics
20%
Phase II Trials
9%
Polyneuropathy
9%
Prednisone
9%
Prevalence
7%
Receptor
28%
Rituximab
28%
Sarcopenia
28%
Sarcopenic Obesity
19%
Survival Prediction
28%
Survival Rate
28%
Trastuzumab
28%
Venetoclax
28%
Nursing and Health Professions
Acute Myeloid Leukemia
28%
Clinical Practice
8%
Confidence Interval
16%
Frailty
28%
Hazard Ratio
16%
Hospital Volume
28%
Induction Chemotherapy
20%
Metastatic Breast Cancer
28%
Multiple Myeloma
28%
Muscle Mass
28%
Myeloma
5%
Overall Survival
57%
Remission
32%
Sarcopenic Obesity
19%
Survival Prediction
28%
Treatment Duration
8%